Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
2008 Standout
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
2011 Standout
Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma
2008
Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer
2002
Intracellular Delivery System for Antibody–Peptide Drug Conjugates
2015 StandoutNobel
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Sensitive liquid chromatography–mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma
2002
Effects of Roselle (Hibiscus sabdariffa Linn.), a Thai Medicinal Plant, on the Mutagenicity of Various Known Mutagens in Salmonella typhimurium and on Formation of Aberrant Crypt Foci Induced by the Colon Carcinogens Azoxymethane and 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in F344 rats
1999 Standout
The antioxidant role of selenium and seleno-compounds
2003 Standout
Breast cancer
2016 Standout
Selection of adjuvant chemotherapy for treatment of node-positive breast cancer
2005
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer
2004
Natural products: An evolving role in future drug discovery
2011 Standout
Adjuvant Therapy for Very Young Women With Breast Cancer: Need for Tailored Treatments
2001
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
2005 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer
2004
Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force
2015
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Quality of Life in Long-Term, Disease-Free Survivors of Breast Cancer: a Follow-up Study
2002 Standout
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer
2001
Osteopenia and osteoporosis in women with breast cancer
2003
Antibody therapy of cancer
2012 Standout
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
2005
Lycopene as the most efficient biological carotenoid singlet oxygen quencher
1989 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer
2011
A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer
2000
Endothelial cell effects of cytotoxics: balance between desired and unwanted effects
2004
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
2012 Standout
Analysis of anticancer drugs: A review
2011 Standout
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Natural compounds for cancer treatment and prevention
2009 Standout
Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma
2007
Monoclonal Antibodies in the Treatment of Non-Hodgkin???s Lymphoma
2007
Neutrophils in cancer: neutral no more
2016 Standout
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and Neck
1990 Standout
Breast cancer metastasis: markers and models
2005 Standout
Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy
2007
Rituximab-Associated Infections
2010
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Antioxidants and Cancer Therapy: A Systematic Review
2004
Riding the Crest of the Teachable Moment: Promoting Long-Term Health After the Diagnosis of Cancer
2005 Standout
Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer
2006
Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer
2009
Locoregional Recurrence Patterns After Mastectomy and Doxorubicin-Based Chemotherapy: Implications for Postoperative Irradiation
2000
Arsenic round the world: a review
2002 Standout
Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer
2003
The therapeutic use of rituximab in non‐Hodgkin's lymphoma
2006
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
2005 Standout
Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*
2001
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
2006 Standout
Metal interactions in carcinogenesis: enhancement, inhibition
1981
Breast Cancer Treatment
2019 Standout
PREDIAGNOSTIC SERUM SELENIUM AND RISK OF CANCER
1983
A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma
2008
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
2001
Combination therapy in combating cancer
2017 Standout
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
Dietary Carcinogens and Anticarcinogens
1983 StandoutScience
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
2008
Rationale and strategies for chemoprevention of cancer in humans.
1987
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
2006
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience
2004
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
2006 Standout
Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study
2008
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
2014 Standout
Evaluation of CD20, CD22, and HLA-DR Targeting for Radioimmunotherapy of B-Cell Lymphomas
2007
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
2009
Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342
2004
Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv
2001
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
2005 Standout
Intensification of Adjuvant Chemotherapy: 5-Year Results of a Randomized Trial Comparing Conventional Doxorubicin and Cyclophosphamide With High-Dose Mitoxantrone and Cyclophosphamide With Filgrastim in Operable Breast Cancer With 10 or More Involved Axillary Nodes
2001
Works of Manuel Grimaldi being referenced
Serum selenium and reticuloendothelial tumors
1978
Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma—A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network
2005
Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.
1997
Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial
2001